• Je něco špatně v tomto záznamu ?

Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial

T. Mardešič, B. Mannaerts, M. Abuzeid, M. Levy, H. Witjes, BC. Fauser, . ,

. 2014 ; 28 (4) : 462-8.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15008256

To evaluate whether a short follicular phase of ovarian stimulation compromises the chance of pregnancy, subjects from a double-blind, randomized trial treated with a single dose of corifollitropin alfa (n=756) or daily recombinant FSH (n=750) were categorized as early responders if three follicles ≥17 mm were reached and human chorionic gonadotrophin (HCG) was administered prior to or on stimulation day 8, and as normal responders if three follicles ≥17 mm were reached and HCG was administered after stimulation day 8. In the corifollitropin alfa and recombinant FSH groups, 23.2% and 29.1%, respectively, were early responders (P=0.01). Regardless of the treatment group, the initial ovarian response was higher in early responders, but with two extra days of stimulation, the number and size of follicles on the day of HCG in the normal responders was similar to those of the early responders. The number of oocytes was similar in both response groups following corifollitropin alfa treatment (13.6 versus 14.5) and recombinant FSH treatment (12.8, both groups). The ongoing pregnancy rates were comparable for early and normal responders regardless of the treatment group, supporting successful outcome following a stimulation period of only 1 week.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008256
003      
CZ-PrNML
005      
20150331122437.0
007      
ta
008      
150306s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.rbmo.2013.12.009 $2 doi
035    __
$a (PubMed)24581989
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Mardešič, Tonko $u Institut Pronatal, Prague, Czech Republic. Electronic address: Tonko.Mardesic@seznam.cz.
245    10
$a Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial / $c T. Mardešič, B. Mannaerts, M. Abuzeid, M. Levy, H. Witjes, BC. Fauser, . ,
520    9_
$a To evaluate whether a short follicular phase of ovarian stimulation compromises the chance of pregnancy, subjects from a double-blind, randomized trial treated with a single dose of corifollitropin alfa (n=756) or daily recombinant FSH (n=750) were categorized as early responders if three follicles ≥17 mm were reached and human chorionic gonadotrophin (HCG) was administered prior to or on stimulation day 8, and as normal responders if three follicles ≥17 mm were reached and HCG was administered after stimulation day 8. In the corifollitropin alfa and recombinant FSH groups, 23.2% and 29.1%, respectively, were early responders (P=0.01). Regardless of the treatment group, the initial ovarian response was higher in early responders, but with two extra days of stimulation, the number and size of follicles on the day of HCG in the normal responders was similar to those of the early responders. The number of oocytes was similar in both response groups following corifollitropin alfa treatment (13.6 versus 14.5) and recombinant FSH treatment (12.8, both groups). The ongoing pregnancy rates were comparable for early and normal responders regardless of the treatment group, supporting successful outcome following a stimulation period of only 1 week.
650    _2
$a dospělí $7 D000328
650    _2
$a choriogonadotropin $x aplikace a dávkování $7 D006063
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a folikuly stimulující hormon $x aplikace a dávkování $7 D005640
650    _2
$a folikuly stimulující hormon lidský $x aplikace a dávkování $7 D043373
650    _2
$a folikulární fáze $x fyziologie $7 D005498
650    _2
$a lidé $7 D006801
650    _2
$a indukce ovulace $x metody $7 D010062
650    _2
$a těhotenství $7 D011247
650    _2
$a úhrn těhotenství na počet žen v reprodukčním věku $7 D018873
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $7 D011994
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mannaerts, Bernadette $u MSD, The Netherlands.
700    1_
$a Abuzeid, Mostafa $u Center for Reproductive Medicine, Hurley Medical Center, Flint, MI, USA. $7 gn_A_00000938
700    1_
$a Levy, Michael $u Shady Grove Fertility, Rockville, MD, USA.
700    1_
$a Witjes, Han $u MSD, The Netherlands.
700    1_
$a Fauser, Bart C J M $u Department of Reproductive Medicine and Gynecology, University Medical Center, Utrecht, The Netherlands.
700    1_
$a ,
773    0_
$w MED00007348 $t Reproductive biomedicine online $x 1472-6491 $g Roč. 28, č. 4 (2014), s. 462-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24581989 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150331122707 $b ABA008
999    __
$a ok $b bmc $g 1065529 $s 891056
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 28 $c 4 $d 462-8 $i 1472-6491 $m Reproductive biomedicine online $n Reprod Biomed Online $x MED00007348
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Možnosti archivace